Anupam Rasayan India Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/tb3tv99sndjvj9fgkl4o9syj.pdf

Key Takeaways


Revenue Performance & Drivers

Anand Desai: "I am pleased to highlight that within just six months of this financial year, we have already surpassed the total revenue of FY25, demonstrating the resilience of our business model, strong customer relationships, and operational excellence."

Margin Walk & Normalization Path


Balance Sheet & Cash Flow Repair

Vishal Thakkar: "So now business has started giving back cash than what it was absorbing for the last two years."

The CapEx Overhang: Assets Now Ready to Yield

Vishal Thakkar: "The Rs. 1,000 crores that is invested is now asset put to use because it was a combination of the three plants which we have invested, which are going to now start yielding the revenue because those were under construction." [10-11]

Customer Behavior & Working Capital History


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth50%+ growth for FY26, driven by agrochemical recovery, pharma and polymersFY26
EBITDA marginStabilize at ~25% (±1%) as new contracts and pricing take effectFrom Q3 FY26 onward
Working capital daysReduce to 200 days in the near termNear term, with more meaningful results over 18 months
Operating cash flowContinue delivering Rs. 300+ crore from operationsOngoing
Intercompany cash receiptReceive Rs. 350 crore from US/Europe subsidiariesCurrent quarter/month
New plant revenue contributionRevenue from the completed Rs. 678 crore CapEx to begin flowingFrom here onward

Key Metrics

MetricQ2 FY26
Revenue from operations₹731.40 cr, up 148.8% YoY and 50.5% QoQ
H1 FY26 revenue from operations₹1,217.22 cr, up 122.1% YoY; surpassed full FY25 revenue in six months
EBITDA (incl. other income)₹143.58 cr, up 74.4% YoY; margin of 19.5%
H1 FY26 EBITDA margin~25.5%, slightly subdued due to dispatches from older inventory
Profit after tax₹57.15 cr, up 86.6% YoY; PAT margin of 7.8%
H1 FY26 PAT₹105.61 cr, up 146.6% YoY; PAT margin of 8.6%
FY26 revenue growth guidance50%+, driven by agro recovery and growth in polymer and pharma
EBITDA margin guidance~25%, with a variation of plus or minus 1 ppt
Order book~₹14,646 cr, spread over 5–7 years
Exports share of revenue58% of total revenue
Top 10 customer concentration81% of revenue from operations
Life Science Related Specialty Chemicals share84% of H1 FY26 revenue
Pharma segment YoY growth201% in H1 FY26; 23% of total H1 revenue
Performance Materials YoY growth306% in H1 FY26; 16% of total H1 revenue
Revenue from older inventory liquidation25%–30% of Q2 revenue
Net debt₹730 cr at consolidated level, after repaying ₹175 cr of term debt from warrant proceeds
Working capital days247 days in H1 FY26, down from 409 days in FY25; near-term target of 200 days
Operating cash flow (consolidated)Over ₹350 cr in H1 FY26
Tanfac Industries H1 FY26 revenue₹344.7 cr, up 66.6% YoY